Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Basu

Showing results (141-150 of 183) with videos related to

Pageof 19
Sort By:
Oncoimmunology|November 18, 2017
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survivalIrene Y Cheung, Brian H Kushner, Shakeel Modak, et al.
Pediatric Blood & Cancer|June 17, 2020
Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experienceAmi Patel, Cheryl Fischer, Yi-Chih Lin, et al.
Methods in Enzymology|January 1, 1987
GlycolipidsM Basu, T De, K K Das, et al.
Vaccines|June 27, 2024
Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer VaccineIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
Plant Physiology|March 20, 2013
The manipulation of auxin in the abscission zone cells of Arabidopsis flowers reveals that indoleacetic acid signaling is a prerequisite for organ sheddingManojit M Basu, Zinnia H González-Carranza, Sayed Azam-Ali, et al.
International Journal of Cancer|February 11, 2026
A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remissionBrian H Kushner, Shakeel Modak, Charlie White, et al.
Acta Biochimica Polonica|November 20, 1998
Hydrophobic nature of mammalian ceramide glycanases: purified from rabbit and rat mammary tissuesM Basu, S Dastgheib, M A Girzadas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?Nai-Kong V Cheung, Shakeel Modak, Irina Ostrovnaya, et al.
Journal of Virology|November 23, 2000
Functional mapping of protective domains and epitopes in the rotavirus VP6 proteinA H Choi, M Basu, M M McNeal, et al.
International Journal of Cancer|January 10, 2026
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remissionBrian H Kushner, Charlie White, Audrey Mauguen, et al.
Pageof 19

Showing results (141-150 of 183) with videos related to

Sort By:
Pageof 19
Oncoimmunology|November 18, 2017
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survivalIrene Y Cheung, Brian H Kushner, Shakeel Modak, et al.
Pediatric Blood & Cancer|June 17, 2020
Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experienceAmi Patel, Cheryl Fischer, Yi-Chih Lin, et al.
Methods in Enzymology|January 1, 1987
GlycolipidsM Basu, T De, K K Das, et al.
Vaccines|June 27, 2024
Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer VaccineIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
Plant Physiology|March 20, 2013
The manipulation of auxin in the abscission zone cells of Arabidopsis flowers reveals that indoleacetic acid signaling is a prerequisite for organ sheddingManojit M Basu, Zinnia H González-Carranza, Sayed Azam-Ali, et al.
International Journal of Cancer|February 11, 2026
A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remissionBrian H Kushner, Shakeel Modak, Charlie White, et al.
Acta Biochimica Polonica|November 20, 1998
Hydrophobic nature of mammalian ceramide glycanases: purified from rabbit and rat mammary tissuesM Basu, S Dastgheib, M A Girzadas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?Nai-Kong V Cheung, Shakeel Modak, Irina Ostrovnaya, et al.
Journal of Virology|November 23, 2000
Functional mapping of protective domains and epitopes in the rotavirus VP6 proteinA H Choi, M Basu, M M McNeal, et al.
International Journal of Cancer|January 10, 2026
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remissionBrian H Kushner, Charlie White, Audrey Mauguen, et al.
Pageof 19